Clinical trials: Gastrointestinal Tract
Cystic Fibrosis
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
This is a Phase 3, 2-part (Part A and Part B), open-label, multicenter study evaluating the pharmacokinetics (PK), safety, tolerability, and pharmacodynamics (PD) of multiple doses of lumacaftor/ivacaftor (LUM/IVA) in subjects 2…
- Trial name
- NCT02797132
- Testing
- LUM/IVA
- Where
- 20 sites in United States, Canada
- Volunteers
- 62 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age
A study to determine the safety, effectiveness, and acceptability of 2 methods of administration of EUR-1008 (APT-1008) (Zenpep® [pancrelipase] delayed release capsule) 3,000 lipase units capsule, a pancreatic enzyme product…
- Trial name
- NCT01100606
- Testing
- EUR-1008 (APT-1008)
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Forest Laboratories
Type 2 Diabetes, Chronic Obstructive Pulmonary Disease
Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease
This trial is a randomized, double-blind, parallel placebo clinical trial, the purpose of which is to investigate whether the adjuvant therapy of using probiotics during the treatment of diabetic patients can decrease blood sugar…
- Trial name
- NCT05492448
- Testing
- L. salivarius AP-32 and L. reuteri GL-104, L. reuteri GL-104
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Glac Biotech Co., Ltd
Advanced Solid Tumors
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
- Trial name
- NCT03861793
- Testing
- ALKS 4230, Pembrolizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 116 people
- Sponsor
- Mural Oncology, Inc
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Healthy Subjects
The Effects of Fermented Brown Seaweed Intake on Glucose Metabolism and Gut Health
The aim of this randomised, controlled, cross-over study is to investigate whether the intake of fermented brown seaweed can lower postprandial blood glucose levels and influence the composition of the gut microbiota in 25…
- Trial name
- SEAPRO01 (NCT06418763)
- Testing
- Baobab spread mixed with fermented brown seaweed, Baobab spread
- Where
- Sweden
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Aventure AB
Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
- Trial name
- NCT07145255
- Testing
- ADC
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- MBrace Therapeutics
Ewings Sarcoma, Non Small Cell Lung Cancer
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Autologous Vigil™ vaccine expresses rhGMCSF and bi-shRNAfurin from the Vigil™ plasmid. The GMCSF protein is a potent stimulator of the immune system, recruiting immune effectors to the site of intradermal injection and promoting…
- Conditions
- Ewings Sarcoma, Non Small Cell Lung Cancer, Liver Cancer
- Trial name
- NCT01061840
- Testing
- Vigil™
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Gradalis, Inc.
Cough
Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher
This study is for therapeutic confirmation of AG1321001 to evaluate the safety and efficacy as an anti-tussive agent in cough patients.
- Trial name
- NCT00380315
- Testing
- AG1321001(drug)
- Where
- South Korea
- Volunteers
- 396 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Healthy Subjects
Effect of Proton Pump Inhibitors on Gut Microbiota Composition and Metabolites in Healthy Subjects Using CapScan
This study is designed to evaluate the effect of proton pump inhibitors on the regional composition of the gut microbiota and metabolic profiles of health volunteers using the CapScan collection capsule.
- Trial name
- NCT07054593
- Testing
- CapScan
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Envivo Bio Inc
NSCLC Stage IIIB, NSCLC Stage IV
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
This is a phase I clinical study. Blood is drawn from the patient and brought to our laboratory for isolation of immune cells. These immune cells are then proliferated over a two week period and used to produce our patented…
- Conditions
- NSCLC Stage IIIB, NSCLC Stage IV, Hepatocellular Carcinoma by BCLC Stage, Lung Cancer
- Trial name
- NCT03515252
- Testing
- Immune Killer Cells (IKC)
- Volunteers
- 20 people
- Sponsor
- Ivy Life Sciences, Co., Ltd
Ovarian Cancer, Hepatocellular Carcinoma
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03836352
- Testing
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Where
- 23 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Cystic Fibrosis
Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
The purpose of this research study is to evaluate the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by inhalation (breathed into the lungs) three times a…
- Trial name
- NCT00043316
- Testing
- interferon gamma-1b
- Where
- 17 sites in United States
- Volunteers
- 66 people
- Sponsor
- InterMune
Formula Milk, Infants
Infant Formula Study With Pre- And Postbiotics
This prospective, single-arm study evaluates the gastrointestinal tolerance, safety, and growth, quality of life and gut microbiome development of healthy term infants fed a commercially available palm oil free infant formula…
- Trial name
- NCT07734532
- Testing
- Infant Formula
- Where
- Ireland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Nutricia UK Ltd
Alpha 1-Antitrypsin Deficiency
A Study of Belcesiran in Patients With AATLD
This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ AATD-associated liver disease (AATLD).
- Trial name
- ESTRELLA (NCT04764448)
- Testing
- Belcesiran
- Where
- 23 sites in United States, Australia and 12 more
- Volunteers
- 16 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Fecal Gut Microbiota
National Cohort Study on Infant Gut Microbiota and Nutrition
This study plans to collect 106,667 fecal samples from Chinese infants and children under 6 years old, with multi-dimensional stratification based on geographic location, mode of delivery, antibiotic exposure, and developmental…
- Trial name
- NCT07705685
- Testing
- Fecal sample collection and gut microbiome profiling
- Where
- China
- Volunteers
- 106,667 people
- Sponsor
- DiproBio (Shanghai) Co., Ltd.
Biliary Tract Cancer
Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
To investigate onset of adverse drug reactions in patients with curatively unresectable biliary tract cancer who receive IMFINZI in combination with gemcitabine hydrochloride and cisplatin under actual use in the post-marketing…
- Trial name
- NCT05835778
- Where
- 24 sites in Japan
- Volunteers
- 236 people
- Sponsor
- AstraZeneca
Gastrointestinal Diseases, Ileus
Gut Recovery In Patients Following Surgery
The purpose of the study is to determine if the myoelectrical measurements made by the G-Tech Wireless Patch System correlate with clinical markers of postoperative recovery such as passage of flatus/bowel movement, oral…
- Trial name
- GRIPS (NCT05712525)
- Testing
- G-Tech Wireless Patch System (WPS)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- G-Tech Corporation
GDM
Efficacy of Lactobacillus Rhamnosus LRa05 in Gestational Diabetes
This study aims to comprehensively evaluate the multifaceted impacts of Lactobacillus rhamnosus LRa05 on patients with gestational diabetes.
- Trial name
- NCT06901791
- Testing
- Conventional treatment and Probiotic
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.